- mail us help@24marketresearch.com
- Int'l 1(332) 2424 294 (Int'l)
TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
MARKET INSIGHTS
The global DNA synthesis market size was valued at USD 1.25 billion in 2024. The market is projected to grow from USD 1.44 billion in 2025 to USD 3.29 billion by 2032, exhibiting a robust CAGR of 15.2% during the forecast period.
DNA synthesis refers to the artificial creation of deoxyribonucleic acid (DNA) molecules through chemical or enzymatic methods. This technology enables the precise assembly of nucleotide sequences (A, T, C, G) to construct custom DNA strands for research and commercial applications. The process plays a pivotal role in modern biotechnology, supporting advancements in gene editing, synthetic biology, and therapeutic development.
The market growth is driven by increasing demand for synthetic genes and oligonucleotides across pharmaceutical and biotechnology sectors. Key applications include CRISPR-based gene editing, vaccine development, and molecular diagnostics. The Asia-Pacific region currently dominates with 36% market share, followed by North America (35%) and Europe (26%). Oligonucleotide synthesis holds the largest product segment (53%), while commercial applications account for 74% of total demand.
Expansion of Synthetic Biology Applications Fueling DNA Synthesis Demand
The synthetic biology revolution is creating unprecedented demand for custom DNA synthesis. Synthetic biology applications now span pharmaceuticals, agriculture, industrial biotechnology, and diagnostics, with the global synthetic biology market projected to grow at 21% CAGR through 2030. DNA synthesis serves as the foundational technology enabling researchers to engineer biological systems, with synthetic genes being used to produce everything from mRNA vaccines to sustainable biofuels. Major pharmaceutical companies are increasingly partnering with DNA synthesis providers, with over 300 therapeutic candidates currently in development using synthetic DNA components.
CRISPR Technology Advancements Accelerating Market Growth
CRISPR-based gene editing has become one of the most significant drivers for DNA synthesis, requiring precise synthetic guide RNAs and repair templates. The global CRISPR market is expected to reach $10 billion by 2027, creating substantial demand for high-quality synthetic DNA components. Recent improvements in CRISPR specificity and delivery systems have expanded therapeutic applications, with over 50 clinical trials currently underway for CRISPR-based treatments. This rapid adoption is directly increasing demand for gene fragments and oligonucleotides used in genome editing workflows.
➤ For instance, the development of base editing and prime editing technologies requires increasingly complex synthetic DNA templates, pushing innovation in DNA synthesis platforms.
Furthermore, the integration of artificial intelligence in DNA sequence design is improving synthesis success rates while reducing costs, making synthetic DNA more accessible for research and commercial applications. These technological synergies between gene editing and DNA synthesis are expected to sustain market growth through the next decade.
Stringent Biosecurity Regulations Limiting Commercial Expansion
Growing international concerns about the potential misuse of synthetic DNA have led to increasingly complex regulatory frameworks. Many countries now require synthetic DNA providers to screen orders against pathogen sequences, with compliance costs estimated to add 15-20% to operational expenses. These regulations, while necessary for biosecurity, create significant barriers for smaller DNA synthesis companies trying to operate across multiple jurisdictions. The current patchwork of national regulations also creates uncertainty for companies developing international supply chains.
Supply Chain Vulnerabilities Impacting Market Stability
The DNA synthesis industry faces significant supply chain risks, particularly for critical raw materials like phosphoramidites and nucleoside derivatives. Over 80% of these key inputs are manufactured by a handful of suppliers, creating potential bottlenecks. Recent global disruptions have led to price fluctuations of 30-40% for some synthesis reagents, forcing companies to either absorb costs or pass them to customers. This volatility makes long-term planning challenging and could potentially delay research timelines dependent on synthetic DNA products.
Emerging Markets Present Untapped Growth Potential
While North America and Europe currently dominate DNA synthesis consumption, the Asia-Pacific region is experiencing 22% annual growth in research funding for biotechnology applications. Countries like China, India, and South Korea are making substantial investments in life sciences infrastructure, creating new opportunities for DNA synthesis providers. Local governments are establishing biotech parks and offering incentives that could drive adoption of synthetic biology tools, with over 50 new institutes focused on genetic research planned across the region by 2025.
Automation and AI Integration Transforming Production Capabilities
Advances in laboratory automation and machine learning are creating opportunities to dramatically improve DNA synthesis throughput and accuracy. Next-generation synthesis platforms incorporating AI-driven error correction can achieve error rates below 1 in 10,000 bases, meeting the stringent requirements for therapeutic applications. These technological improvements are reducing synthesis costs by approximately 30% annually, making longer constructs more accessible for research and commercial use. Companies investing in fully automated synthesis facilities are gaining competitive advantages in speed and scalability.
MARKET CHALLENGES
Intellectual Property Complexities Creating Market Barriers
The DNA synthesis industry faces growing challenges related to intellectual property rights, particularly for synthetic genes with therapeutic applications. Patent thickets surrounding foundational technologies can require companies to navigate hundreds of overlapping claims, adding legal costs and delaying product development. Recent court decisions have created uncertainty about the patentability of certain synthetic DNA sequences, potentially affecting investment in novel construct development.
Other Challenges
Quality Control Demands
Increasing application of synthetic DNA in clinical settings requires implementation of stringent quality control measures, with some therapeutic applications demanding purity levels exceeding 99.9%. Meeting these standards while maintaining competitive pricing presents significant technical and economic challenges for synthesis providers.
Data Security Concerns
The digital nature of DNA sequence design and ordering creates vulnerabilities to cyber threats, with bioinformatics systems becoming potential targets for intellectual property theft. Implementing robust cybersecurity measures adds to operational costs while potentially slowing order processing times.
Oligonucleotide Synthesis Leads the Market Due to High Demand in Research and Diagnostics
The market is segmented based on type into:
Oligonucleotide Synthesis
Subtypes: Primers, Probes, and others
Gene Synthesis
Subtypes: Custom gene synthesis and library synthesis
Commercial Segment Dominates with Widespread Use in Pharmaceutical and Biotechnology Industries
The market is segmented based on application into:
Commercial
Pharmaceutical companies
Biotechnology firms
Academic Research
Solid-phase Synthesis Holds Major Share Due to its Reliability and Efficiency
The market is segmented based on technology into:
Solid-phase synthesis
Chip-based synthesis
PCR-based enzymatic synthesis
Others
Innovation and Strategic Expansion Drive Market Leadership in DNA Synthesis
The global DNA synthesis market exhibits moderate fragmentation, with established biotech giants competing alongside specialized synthetic biology firms. GenScript Biotech Corporation currently leads the market, commanding approximately 18% revenue share in 2024, primarily due to its comprehensive service portfolio spanning oligonucleotide synthesis, gene synthesis, and plasmid production. The company's strong foothold in Asia-Pacific (36% regional market share) complements its expanding North American and European operations.
Thermo Fisher Scientific and Integrated DNA Technologies (IDT) maintain robust positions through vertical integration strategies, combining DNA synthesis capabilities with downstream analysis tools. Their dominance in North America (35% market share) stems from extensive R&D collaborations with pharmaceutical companies and academic institutions. Notably, IDT's recent launch of ultra-long oligonucleotide synthesis technology (up to 150 nt) has strengthened its competitive edge in precision medicine applications.
Emerging players like Twist Bioscience are disrupting the market through silicon-based DNA synthesis platforms, achieving 70% cost reductions for high-throughput applications. The company's Gene Synthesis 3.0 platform has gained significant traction among synthetic biology startups, capturing 8% of the commercial segment (74% of total market). Similarly, Eurofins Genomics has expanded its market presence through strategic acquisitions, including the 2023 purchase of BioSpring GmbH to enhance its custom DNA services.
Meanwhile, BBI Solutions and Azenta Life Sciences are focusing on niche applications, particularly in CRISPR gene editing and molecular diagnostics. Their specialized product offerings cater to the growing demand for synthetic DNA components in therapeutic development and point-of-care testing solutions, expected to drive 20% annual growth in these segments through 2032.
GenScript Biotech Corporation (China)
Thermo Fisher Scientific Inc. (U.S.)
Integrated DNA Technologies (U.S.)
Eurofins Genomics (Germany)
DNA 2.0 (ATUM) (U.S.)
BBI Solutions (U.K.)
Azenta Life Sciences (U.S.)
SBS Genetech (China)
Twist Bioscience (U.S.)
OriGene Technologies (U.S.)
Bioneer Corporation (South Korea)
Eton Bioscience (U.S.)
Synbio Technologies (U.S.)
Eurogentec (Belgium)
The global DNA synthesis market is experiencing robust growth, fueled by increasing investments in synthetic biology applications across pharmaceutical, agricultural, and industrial biotechnology sectors. With the market projected to grow at a CAGR of 15.2% from 2024 to 2032, synthetic biology startups raised over $7.8 billion in funding in 2023 alone, demonstrating strong industry confidence. DNA synthesis serves as the foundational technology enabling researchers to design and manufacture genetic constructs for novel therapeutics, biofuels, and biomaterials. The emergence of cell-free protein synthesis systems that utilize synthetic DNA templates has further expanded potential applications in rapid vaccine development and enzyme production, particularly following global demands highlighted during the COVID-19 pandemic.
Automation and AI Integration in Gene Synthesis
Laboratory automation and artificial intelligence are transforming DNA synthesis workflows, enabling faster turnaround times and reducing error rates below 0.1% per base pair in some commercial offerings. Major providers have implemented robotic platforms that can process over 10,000 gene synthesis requests monthly, while machine learning algorithms optimize codon usage for heterologous expression. These technological advancements are particularly critical as the average length of synthesized genes continues to increase, with some pharmaceutical companies now routinely ordering constructs exceeding 10 kilobases for complex therapeutic applications such as antibody development and viral vector production.
The pharmaceutical sector accounts for the majority share of DNA synthesis demand, representing approximately 74% of commercial applications. This dominance stems from accelerating development of DNA-based vaccines, mRNA therapeutics, and viral vectors for gene therapy. Over 500 clinical trials currently utilize synthetic DNA components, with particular growth in personalized cancer vaccines and CRISPR-based therapies requiring custom genetic constructs. Meanwhile, biomanufacturing applications are expanding beyond traditional biologics into areas such as DNA data storage, where synthetic oligonucleotides offer potential solutions for high-density molecular information storage with densities reaching exabytes per gram of DNA material. While these emergent applications show promise, technical challenges around synthesis scalability and error correction continue to shape the competitive landscape.
North America
The North American DNA synthesis market, accounting for 35% of global revenue in 2024, remains a powerhouse driven by cutting-edge biotech research and strong commercial adoption. The U.S. dominates with its concentration of biopharma giants (e.g., Thermo Fisher, IDT) and academic institutions leveraging synthetic DNA for CRISPR and mRNA vaccine development. Significant NIH funding ($48 billion in 2023) accelerates genomic research, while venture capital investments in synthetic biology startups exceeded $3.7 billion in 2022. However, stringent FDA oversight on synthetic biology applications creates both quality benchmarks and commercialization bottlenecks. The region leads in ultra-long gene synthesis (1000+ base pairs), with Twist Bioscience pioneering high-throughput platforms.
Europe
Europe's 26% market share reflects its balanced ecosystem of academic rigor and industrial scale. The EU's Horizon Europe program allocates €95.5 billion for health/biotech R&D, fueling demand for custom oligonucleotides. Germany and the UK are pivotal hubs, hosting Eurofins Genomics and key CRISPR players. Strict compliance with GDPR and the Nagoya Protocol on genetic resource utilization adds procedural complexity but enhances standardization. A notable trend is the rise of sustainable synthesis methods—BASF and Evonik invest in enzyme-based DNA production to reduce chemical waste. While pricing pressures exist due to healthcare budget constraints, precision medicine initiatives sustain growth in therapeutic applications.
Asia-Pacific
As the largest market (36% global share), APAC thrives on China’s synthetic biology boom—its 14th Five-Year Plan prioritizes biotech with $1.4 trillion in strategic funding. Genescript and BBI dominate local supply chains, offering cost-competitive services at 30-40% below Western counterparts. India’s genome sequencing mission and Japan’s Moonshot R&D program drive academic segment growth. The region excels in high-volume oligonucleotide production but lags in IP-heavy gene synthesis due to weaker patent enforcement. Rising automation (e.g., MGI Tech’s robotic synthesizers) and Singapore’s regulatory sandbox for synbio startups present new opportunities despite fragmented quality standards.
South America
With under 5% market penetration, South America shows nascent potential centered in Brazil and Argentina. Agricultural biotech applications dominate—CRISPR-edited crops and livestock diagnostics utilize bespoke DNA constructs. Local players like Neoprospecta Microbiome Technologies leverage synthetic DNA for environmental testing. Chronic challenges include currency volatility (50% BRL depreciation since 2020) and reliance on imported reagents due to limited local manufacturing. Recent Mercosur trade agreements aim to facilitate enzyme and primer imports, but bureaucratic hurdles persist. Growth hinges on public-sector partnerships; Fiocruz’s vaccine R&D exemplifies this trend.
Middle East & Africa
The MEA region, though under 3% of the global market, shows strategic growth pockets. Israel’s thriving biotech scene—including Evogene’s agricultural gene editing—anchors demand, while UAE’s Dubai Genetics Center pioneers Arab genome projects. Saudi Vision 2030 allocates $64 billion for healthcare modernization, indirectly boosting synthetic DNA adoption. Key constraints include scarce cold-chain logistics for temperature-sensitive reagents and limited local expertise—most advanced orders are outsourced to Europe or Asia. South Africa emerges as a potential hub with its robust academic network (e.g., University of Cape Town’s synbio lab), though underfunding remains endemic across Sub-Saharan Africa.
This market research report offers a holistic overview of global and regional DNA Synthesis markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include Genescript, Thermo Fisher Scientific, IDT, Twist Bioscience, BBI, Eurofins Genomics, DNA 2.0 (ATUM), Azenta Life Sciences, and other leading biotechnology firms.
-> Primary growth drivers include rising demand for synthetic genes in drug development, expansion of synthetic biology applications, and increasing R&D investments in biotechnology.
-> Asia-Pacific holds the largest market share at 36%, followed by North America (35%) and Europe (26%).
-> Emerging trends include automated DNA synthesis platforms, AI-driven sequence design, CRISPR-based gene editing applications, and sustainable synthesis methods.
Frequently Asked Questions ?
